A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

@article{Giovannoni2010APT,
  title={A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.},
  author={Gavin Giovannoni and Giancarlo Comi and Stuart D. Cook and Kottil Rammohan and Peter Rieckmann and Per Soelberg S{\o}rensen and Patrick Vermersch and Peter Chang and Anthony Hamlett and Bruno Musch and Steven J. Greenberg},
  journal={The New England journal of medicine},
  year={2010},
  volume={362 5},
  pages={
          416-26
        }
}
BACKGROUND Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis. METHODS We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the… 

Figures and Tables from this paper

Cladribine Tablets

Improvements in the annualized relapse rate with oral cladribine were independent of key baseline patient characteristics which included age, sex, previous treatment with disease-modifying drugs and the number of relapses in the previous 12 months.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Teriflunomide significantly reduced relapse rates, disability progression (at the higher dose), and MRI evidence of disease activity, as compared with placebo.

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

Cladribine Tablets: A Review in Relapsing MS

  • E. Deeks
  • Medicine, Psychology
    CNS Drugs
  • 2018
Active comparisons and longer-term follow-up are beneficial, although current data indicate that for adults with highly active relapsing MS, cladribine tablets are an effective treatment option with the convenience of low-burden, short-course, oral administration.

[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

Cladribine tablets are an important addition to the therapeutic landscape in RMS with patient-friendly short dosing periods and a favorable adverse event profile, which provides a sustained and strong reduction of MS disease activity.

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

A review of all safety data, including lymphopenia, infections, and malignancies, is provided based on data from all trials in patients with MS, including the initial parenteral formulation studies.

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

The safety and tolerability profile observed in the CLARITY study together with the reported efficacy support the potential for cladribine tablets as an MS therapy.

Oral cladribine and fingolimod for relapsing multiple sclerosis.

  • H. Mann
  • Medicine, Psychology
    The New England journal of medicine
  • 2010
Support is needed for the assertions that the FREEDOMS and CLARITY trials were conducted in accordance with the Declaration of Helsinki and a number of investigators participating in these two trials were coauthors of an article concerning the ethical use of placebos in trials for multiple sclerosis.
...

References

SHOWING 1-10 OF 19 REFERENCES

The treatment of chronic progressive multiple sclerosis with cladribine.

In the first year the most striking finding was that while clinical deterioration continued in the placebo-treated patients, the condition of patients who received cladribine stabilized or even improved slightly, and toxicity and therapeutic response were dose-related.

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.

It is concluded that cladribine shows promise as a treatment for relapsing-remitting multiple sclerosis.

A Double‐Blind, Placebo‐Controlled, Randomized Trial of Cladribine in Relpaasing‐Remitting Multiple Sclerosis

It is concluded that cladribine shows promise as a treatment for relpaasing-remitting multiple sclerosis.

Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.

Results obtained indicate fast and long-lasting decrease of serum leucocyte level and suppressive influence of cladribine treatment on immune processes in multiple sclerosis patients.

Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.

There was a significant beta 2M decrease in sera but not in CSF in MS patients after the cladribine treatment, associated with a slight but significant clinical improvement measured by Kurtzke's Expanded Disability Status Scale.

Emerging oral therapies for multiple sclerosis

Alternative MS treatments with less invasive routes of administration and new modes of action are needed to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efficacy.

Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.

This review provides a compilation of novel immunotherapeutic strategies or new aspects of known immunotherAPEutic agents which have evolved recently and the pathogenetic rationale of these novel drug targets for the treatment of MS are highlighted.

Interleukin‐8 and RANTES levels in patients with relapsing–remitting multiple sclerosis (RR‐MS) treated with cladribine

The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines – interleukin‐8 (IL‐8) and RANTES (regulated on activation, normal T cell expressed and secreted).

The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis

  • T. Chitnis
  • Biology, Medicine
    International Review of Neurobiology
  • 2007